What rheumatologists should know about orofacial manifestationsof autoimmune rheumatic diseases;O que o reumatologista deve saber sobre as manifestações orofaciais das doenças reumáticas autoimunes

Revista Brasileira de Reumatologia

Volumn 56, Issue 5, 2016, Pages 441-450

  Abrão, Aline Lauria Pires ^a   Santana, Caroline Menezes ^a   Bezerra, Ana Cristina Barreto ^a   de Amorim, Rivadávio Fernandes Batista ^a   da Silva, Mariana Branco ^a   da Mota, Licia Maria Henrique ^b   Falcãob, Denise Pinheiro ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

Author keywords

Autoimmune rheumatic diseases; Oral lesions; Orofacial manifestations; Periodontal disease; Saliva

Indexed keywords

ARTICLE; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; DISEASE ACTIVITY; DYSPHAGIA; DYSPHONIA; FACE DISORDER; HUMAN; HYPOSALIVATION; MOUTH DISEASE; MYOSITIS; PERIODONTAL DISEASE; RELAPSING POLYCHONDRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SJOEGREN SYNDROME; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TEMPOROMANDIBULAR JOINT DISORDER; XEROSTOMIA; DIFFERENTIAL DIAGNOSIS; PATHOLOGY; PSYCHOLOGY; RHEUMATOLOGIST; SEVERITY OF ILLNESS INDEX;

AUTOIMMUNE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATIC DISEASES; RHEUMATOLOGISTS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84994302363     PISSN: 04825004     EISSN: 18094570     Source Type: Journal    
DOI: 10.1016/j.rbr.2015.08.011     Document Type: Short Survey

References (70)

1. Mosca M, Chiara T, Rosaria T, Stefano B. Undifferentiatedconnective tissue diseases (UCTD): simplified systemicautoimmune diseases. Autoimmun Rev. 2011;10(5):256-8.
2. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R,Kwoh CK, et al. Estimates of the prevalence of arthritis andother rheumatic conditions in the United States: Part I.Arthritis Rheum. 2008;58(1):15-25.
3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, BirnbaumNS, et al. 2010 rheumatoid arthritis classification criteria: anAmerican College of Rheumatology/European League AgainstRheumatism collaborative initiative. Arthritis Rheum.2010;62(9):2569-81.
4. Sidebottom A, Salha R. Management of thetemporomandibular joint in rheumatoid disorders. Br J OralMaxillofac Surg. 2013;51(3):191-8.
5. Aliko A, Ciancaglini R, Alushi A, Tafaj A, Ruci D.Temporomandibular joint involvement in rheumatoidarthritis: systemic lupus erythematosus and systemicsclerosis. Int J Oral Maxillofac Surg. 2011;40(7):704-9.
6. Takahashi T, Kondoh T, Fukuda M, Yamazaki Y, Toyosaki T,Suzuki R. Proinflammatory cytokines detectable in synovialfluids from patients with temporomandibular disorders. OralSurg Oral Med Oral Pathol Oral Radiol Endodontol.1998;85(2):135-41.
7. Kaneyama K, Segami N, Nishimura M, Suzuki T, Sato J.Importance of proinflammatory cytokines in synovial fluidfrom 121 joints with temporomandibular disorders. Br J OralMaxillofac Surg. 2002;40(5):418-23.
8. Melchiorre D, Calderazzi A, Bongi SM, Cristofani R, Bazzichi L,Eligi C, et al. A comparison of ultrasonography and magneticresonance imaging in the evaluation of temporomandibularjoint involvement in rheumatoid arthritis and psoriaticarthritis. Rheumatology. 2003;42(5):673-6.
9. Manfredini D, Guarda-Nardini L, Winocur E, Piccotti F, AhlbergJ, Lobbezoo F. Research diagnostic criteria fortemporomandibular disorders: a systematic review of axis Iepidemiologic findings. Oral Surg Oral Med Oral Pathol OralRadiol Endodontol. 2011;112(4):453-62.
10. Cannizzaro E, Schroeder S, Muller LM, Kellenberger CJ,Saurenmann RK. Temporomandibular joint involvement inchildren with juvenile idiopathic arthritis. J Rheumatol.2011;38(3):510-5.
11. Scrivani SJ, Keith DA, Kaban LB. Temporomandibulardisorders. N Engl J Med. 2008;359(25):2693-705.
12. Roldán-Barraza C, Janko S, Villanueva J, Araya I, Lauer HC. ASystematic Review and Meta-analysis of Usual TreatmentVersus Psychosocial Interventions in the Treatment ofMyofascial Temporomandibular Disorder Pain. J OralFacialPain Headache. 2013;28(3):205-22.
13. Klasser GD, Balasubramaniam R, Epstein J. Topicalreview-connective tissue diseases: orofacial manifestationsincluding pain. J Orofac Pain. 2007;21(3):171-84.
14. Petersen PE, Ogawa H. Strengthening the prevention ofperiodontal disease: the WHO approach. J Periodontol.2005;76(12):2187-93.
15. Bascones-Martinez A, Matesanz-Perez P, Escribano-BermejoM, González-Moles M-á, Bascones-Ilubdain J, Meuman J-H,et al. Periodontal disease and diabetes -Review of theliterature. Med Oral Patol Oral Cir Bucal. 2011;16(6):e722-9.
16. Hitchon CA, Chandad F, Ferucci ED, Willwmze A,Ioan-Facsinay A, van der Woude D, et al. Antibodies toPorphyromonas gingivalis are associated withanticitrullinated protein antibodies in patients withrheumatoid arthritis and their relatives. J Rheumatol.2010;37(6):1105-12.
17. Berthelot JM, Goff BL. Rheumatoid arthritis and periodontaldisease. Joint Bone Spine. 2010;77(6):537-41.
18. Ogrendik M, Kokino S, Ozdemir F, Bird PS. Serum antibodiesto oral anaerobic bacteria in patients with rheumatoidarthritis. Medscape Gen Med. 2005;7(2):2.
19. Mercado F, Marshall RI, Klestov AC, Bartold PM. Relationshipbetween rheumatoid arthritis and periodontitis. J Periodontol.2001;72(6):779-87.
20. Pischon N, Roehner E, Hocke A, Guessan PN, Müller HC,Matziolis G, et al. Effects of Porphyromonas gingivalis on cellcycle progression and apoptosis of primary humanchondrocytes. Ann Rheum Dis. 2009;68(12):1902-7.
21. Detert J, Pischon N, Burmester GR, Buttgereit F. Theassociation between rheumatoid arthritis and periodontaldisease. Arthritis Res Ther. 2010;12(5):218.
22. De Smit MJ, Brouwer E, Vissink A, van Winkelhoff AJ.Rheumatoid arthritis and periodontitis; a possible link viacitrullination. Anaerobe. 2011;17(4):196-200.
23. Preshaw PM, Taylor JJ. How has research into cytokineinteractions and their role in driving immune responsesimpacted our understanding of periodontitis? J ClinPeriodontol. 2011;38(s11):60-84.
24. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ.Periodontitis in RA-the citrullinated enolase connection. NatRev Rheumatol. 2010;6(12):727-30.
25. Tonetti MS, D'Aiuto F, Nibali L, Donald A, Storry C, Parkar M,et al. Treatment of periodontitis and endothelial function. NEngl J Med. 2007;356(9):911-20.
26. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, MattesonEL. Occurrence of extraarticular disease manifestations isassociated with excess mortality in a community basedcohort of patients with rheumatoid arthritis. J Rheumatol.2002;29(1):62-7.
27. Andonopoulos A, Drosos AA, Skopouli FN, Moutsopoulos HM.Sjogren's syndrome in rheumatoid arthritis and progressivesystemic sclerosis. A comparative study. Clin Exp Rheumatol.1988;7(2):203-5.
28. Russell SL, Reisine S. Investigation of xerostomia in patientswith rheumatoid arthritis. J Am Dental Assoc (1939).1998;129(6):733-9.
29. Guobis Z, Baseviciene N, Paipaliene P. Aspects of xerostomiaprevalence and treatment among rheumatic inpatients.Medicina (Kaunas, Lithuania). 2007;44(12):960-8.
30. Falcão DP, Mota LMHD, Pires AL, Bezerra ACB. Sialometry:aspects of clinical interest. Rev Brasil Reumatol.2013;53(6):525-31.
31. Scola R, Werneck L, Prevedello D. Polimiosite edermatomiosite. Dendrito, Curitiba. 1999;4:77-82.
32. Yazici Y, Kagen LJ. Clinical presentation of the idiopathicinflammatory myopathies. Rheum Dis Clin N Am.2002;28(4):823-32.
33. Lundberg IE, Dastmalchi M. Possible pathogenic mechanismsin inflammatory myopathies. Rheum Dis Clin N Am.2002;28(4):799-822.
34. Gibson J, Lamey PJ, Zoma A, Ballantyne J. Tongue atrophy inmixed connective tissue disease. Oral Surg Oral Med OralPathol. 1991;71(3):294-6.
35. Mastaglia FL, Ojeda VJ. Inflammatory myopathies: part 1. AnnNeurol. 1985;17(3):215-27.
36. Tanaka TI, Geist SMRY. Dermatomyositis: a contemporaryreview for oral health care providers. Oral Surg Oral Med OralPathol Oral Radiol. 2012;114(5):e1-8.
37. Oh THE, Brumfield KA, Hoskin TL, Stolp KA, Murray JA,Basford JR. Dysphagia in inflammatory myopathy: clinicalcharacteristics, treatment strategies, and outcome in 62patients. Mayo Clin Proc. 2007;82(4):441-7.
38. Tanaka TI, Geist SRY. Dermatomyositis: a contemporaryreview for oral health care providers. Oral Surg Oral Med OralPathol Oral Radiol. 2012;114(5):e1-8.
39. Márton K, Hermann P, Dankó K, Fejérdy P, Madléna M, Nagy G.Evaluation of oral manifestations and masticatory force inpatients with polymyositis and dermatomyositis. J OralPathol Med. 2005;34(3):164-9.
40. Brennan MT, Patronas NJ, Brahim JS. Bilateral condylarresorption in dermatomyositis A case report. Oral Surg OralMed Oral Pathol Oral Radiol Endodontol. 1999;87(4):446-51.
41. Huber AM, Dugan EM, Lachenbruck PA, Feldman BM, PerezMD, Zemel LS, et al. Preliminary validation and clinicalmeaning of the Cutaneous Assessment Tool in juveniledermatomyositis. Arthritis Care Res. 2008;59(2):214-21.
42. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, BoguniewiczM, Eigenmann P, et al. Diagnosis and treatment of atopicdermatitis in children and adults: European Academy ofAllergology and Clinical Immunology/American Academy ofAllergy, Asthma and Immunology/PRACTALL ConsensusReport. Allergy. 2006;61(8):969-87.
43. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. Newinsights into the pathogenesis of systemic sclerosis.Autoimmun Rev. 2003;2(3):152-7.
44. Katsambas A, Stefanaki C. Life-threatening dermatoses dueto connective tissue disorders. Clin Dermatol. 2005;23(3):238-48.
45. Silman A. Scleroderma-demographics and survival. JRheumatol. 1997; Supplement 48: 58-61.
46. Yuen HK, Marlow NM, Reed SG, Mahoney S, Summerlin LM,Leite R, et al. Effect of orofacial exercises on oral aperture inadults with systemic sclerosis. Disabil Rehabil.2012;34(1):84-9.
47. Alanta A, Cabane J, Hachulla E, Princ G, Ginisty D, Hassin M,et al. Recommendations for the care of oral involvement inpatients with systemic sclerosis. Arthritis Care Res.2011;63(8):1126-33.
48. Nagy G, Kovács J, Zeher M, Czirják L. Analysis of the oralmanifestations of systemic sclerosis. Oral Surg Oral Med OralPathol. 1994;77(2):141-6.
49. Al-Rayes H, Al-Swailem R, Arfin M, Sobki S, Rizvi S, Tariq M.Lupus Around the World Systemic lupus erythematosus andinfections: a retrospective study in Saudis. Lupus.2007;16(9):755-63.
50. Hay EM, Bacon PA, Gordon C, Isenberg DA. The BILAG index: areliable and valid instrument for measuring clinical diseaseactivity in systemic lupus erythematosus. QJM.1993;86(7):447-58.
51. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,Austin A, et al. Derivation of the SLEDAI. A disease activityindex for lupus patients. Arthritis Rheum. 1992;35(6):630-40.
52. Liang MH, Socher SA, Larson MG, Schur PH. Reliability andvalidity of six systems for the clinical assessment of diseaseactivity in systemic lupus erythematosus. Arthritis Rheum.1989;32(9):1107-18.
53. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML,Sciuto M, et al. Disease activity in systemic lupuserythematosus: report of the Consensus Study Group of theEuropean Workshop for Rheumatology Research. II.Identification of the variables indicative of disease activityand their use in the development of an activity score. TheEuropean Consensus Study Group for Disease Activity in SLE.Clin Exp Rheumatol. 1991;10(5):541-7.
54. Brennan MT, Valerin MA, Napeñas JJ, Lockhart PB. Oralmanifestations of patients with lupus erythematosus. DentClin N Am. 2005;49(1):127-41.
55. Mays JW, Sarmadi M, Moutsopoulos NM. Oral manifestationsof systemic autoimmune and inflammatory diseases:diagnosis and clinical management. J Evidence Based DentPract. 2012;12(3):265-82.
56. Albilia JB, Lam DK, Clokie CM, Sándor GK. Systemic lupuserythematosus: a review for dentists. J Can Dent Assoc.2007;73(9):823-30.
57. Kassan SS. HM Moutsopoulos Clinical manifestations andearly diagnosis of Sjogren syndrome. Arch Intern Med.2004;164(12):1275.
58. Dawson LJ, Smith PM, Moots RJ, Field ES. Sjogren'ssyndrome-time for a new approach. Rheumatology (Oxford).2000;39(3):234-7.
59. Barbieri R, Chiereghin A. Síndrome de Sjögren. TemasReumatol Clín. 2009;10(3):88-93.
60. Falcão DP, Leal SC, Vieira CN, Wolff A, Almeida TF, Nunes FP,et al. Sialometry of upper labial minor glands: a clinicalapproach by the use of weighing method Schirmer's teststrips paper. Sci World J. 2014:268634.
61. Tanner K, Pierce JL, Merrill RM, Miller KL, Kendall KA, Roy N.The Quality of Life Burden Associated With Voice Disorders inSjögren's Syndrome. Ann Otol Rhinol Laryngol.2015;124:721-7.
62. Lanfranchi H, Ansola M. Dry Mouth and Nutrition Quality ofLife in Patients With Sjögren Syndrome. Oral Surg Oral MedOral Pathol Oral Radiol. 2013;116(6):e499.
63. Gandía M, Morales-Espinoza EM, Martín-González RM,Retamozo S, Kostov B, Belenguer-Prieto R, et al. Factorsinfluencing dry mouth in patients with primary Sjögrensyndrome: usefulness of the ESSPRI index. Oral Health DentManage. 2014;13(2):402-7.
64. Miedany YE, Ahmed I, Mourad HG, Mehanna AN, Aty SA,Gamal HM, et al. Quantitative ultrasonography and magneticresonance imaging of the parotid gland: can they replace thehistopathologic studies in patients with Sjogren's syndrome?Joint Bone Spine. 2004;71(1):29-38.
65. Strietzel FP, Lafaurie GI, Mendoza GR, Alajbeg I, Pejda S,Vuletic L, et al. Efficacy and safety of an intraoralelectrostimulation device for xerostomia relief: a multicenter,randomized trial. Arthritis Rheum. 2011;63(1):180-90.
66. Furness S, Worthington HV, Bryan G, Birchenough S,McMillian R. Interventions for the management of dry mouth:topical therapies. Cochrane Database Syst Rev.2011;7:CD008934.
67. Anderson LA, Orchardson R. The effect of chewingbicarbonate-containing gum on salivary flow rate and pH inhumans. Arch Oral Biol. 2003;48(3):201-4.
68. Bijella MF, Brighenti FL, BuzalafI MAR. Fluoride kinetics insaliva after the use of a fluoride-containing chewing gum.Braz Oral Res. 2005;19(4):256-60.
69. Lakshman AR, Babu GS, Rao S. Evaluation of effect oftranscutaneous electrical nerve stimulation on salivary flowrate in radiation induced xerostomia patients: A pilot study. JCancer Res Ther. 2015;11(1):229.
70. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X.Treatment of primary Sjögren syndrome: a systematic review.JAMA. 2010;304(4):452-60.